UCLA researchers identify a gene as a potential target in treatment-resistant brain cancer glioblastoma multiforme
Research led by doctors and scientists at UCLA Jonsson Comprehensive Cancer Center and the UCLA Jane & Terry Semel Institute for Neuroscience & Human Behavior has identified a gene that may provide a therapeutic target for the deadly, treatment-resistant brain cancer glioblastoma multiforme (GBM).
The gene, P300, enables GBM cells that have been damaged by radiation therapy to recover by rearranging DNA and initiating a molecular mechanism that refortifies tumor cells for growth and survival. Blocking P300 disrupted its ability to set this process in motion, according to the researchers, who conducted their studies in mouse models and in human GBM cells. Their results appear online in Nature Communications.
Although glioblastoma is considered rare – about 13,000 new cases are expected to be diagnosed in the United States this year, according to the National Brain Tumor Society – it is the most common primary brain tumor in adults. There is no known cure, and the average length of survival is measured in months. GBM cells and their precursors, glioma stem cells (GSC), quickly adapt and recover from injury, so chemotherapy and radiation therapy, which may initially slow a tumor’s progress, can ultimately contribute to growth and recurrence..
By performing single-cell transcriptomic sequencing, which can identify molecular changes in cancerous cells, the UCLA-led research team showed that radiation therapy-induced stress promotes phenotypic conversion of glioma stem cells to resemble two types of cells that are normally found in blood vessels (vascular endothelial-like cells and pericyte-like cells). They found that these converted cells promoted tumor growth and post-treatment recurrence. The conversion was brought about by changes within specific vascular gene regions in a process mediated by the gene P300, or P300 HAT (histone acetyltransferase).
“Our findings show at the single-cell level that ‘radiation-stress’ alters the functional states of glioma cells, but instead of reconstituting the vascular system to carry blood supply, as has sometimes been theorized, these converted cells provide trophic support that enables the cancer cells to survive and grow under the hostile conditions created by radiation,” said senior author Harley Kornblum, M.D., Ph.D., a researcher at the UCLA Jonsson Comprehensive Cancer Center and the UCLA Brain Research Institute.
“Just as P300 plays a key role in changing the molecular landscape of glioma stem cells, inhibiting the gene’s function appears to block the phenotypic conversion. This suggests that small molecules that inhibit P300 HAT activity may be useful in preventing tumor growth and adaptive resistance of GBM,” said Dr. Sree Deepthi Muthukrishnan, Assistant Project Scientist and the first author of the study.
While the authors were able to identify some candidate factors expressed by the vascular-like cells and their experiments show those factors’ potential role in promoting proliferation of radiated tumor cells, they say that further studies will be needed to fully uncover the underlying mechanisms at play. Importantly though, the factors that mediate the trophic actions of radiation-induced vascular-like cells would likely be targets for potential therapeutic intervention to prevent GBM relapse.
Authors UCLA authors include Sree Deepthi Muthukrishnan, Riki Kawaguchi, Pooja Nair, Rachna Prasad, Yue Qin, Maverick Johnson, Qing Wang, Nathan VanderVeer-Harris, Amy Pham, Alvaro G. Alvarado, Michael C. Condro, Fuying Gao, Raymond Gau, Arjun Deb, Jason D. Hinman, Frank Pajonk, Daniel H. Geschwind, and Harley I. Kornblum. Additional authors include Maria G. Castro and Pedro R. Lowenstein, the University of Michigan Medical School; Terry C. Burns, Mayo Clinic, Minnesota; and Steven A. Goldman, University of Rochester Medical Center, New York, and the University of Copenhagen School of Medicine, Denmark.
Funding This work was funded by Broad Stem cell postdoctoral fellowship (SDM), UCLA, The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (RK, SAG, DHG, HIK), the UCLA SPORE in Brain Cancer P50 CA211015-01A1 (FP, HIK), NIH RO1NS121617 (HK), NIH R01HL149687 (AD), NIH R01CA200234 (FP) and the UCLA Intellectual and Developmental Disability Research Center P50 HD103557 (HIK).
Potential Conflict Statement The authors declare no competing interests.
Article: P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells; Nature Communications; Published online 19 October 2022 DOI: 10.1038/s41467-022-33943-0.